AL amyloidosis of the kidney Medical Services in China

AL amyloidosis of the kidney is a rare, systemic plasma cell disorder characterized by the deposition of monoclonal immunoglobulin light chains (predominantly lambda) as insoluble, β-pleated sheet amyloid fibrils in renal tissue. These deposits disrupt normal glomerular and tubulointerstitial architecture, leading to progressive proteinuria, nephrotic syndrome, and ultimately end-stage kidney disease if untreated. Pathogenesis begins with clonal expansion of bone marrow plasma cells producing misfolded, aggregation-prone light chains. Unlike multiple myeloma, the plasma cell burden is typically low (<10% in bone marrow), but the secreted light chains are inherently unstable and prone to proteolytic cleavage and fibril formation. Once deposited in the kidney—especially in glomeruli, blood vessels, and interstitium—they trigger chronic inflammation, podocyte injury, endothelial dysfunction, and capillary basement membrane thickening. Epidemiologically, AL amyloidosis affects approximately 8–12 per million people annually worldwide; renal involvement occurs in over 70% of cases at diagnosis, making it the most common organ manifestation. It predominantly affects adults aged 60–75 years, with a slight male predominance (male:female ≈ 1.3:1). Risk factors include advancing age, undiagnosed monoclonal gammopathy of undetermined significance (MGUS), chronic inflammatory conditions, and genetic polymorphisms in genes involved in protein folding and clearance (e.g., SERPINA1, RBP4). Notably, no strong environmental or lifestyle risk factors have been established. Quality of life is profoundly impacted: patients frequently experience debilitating fatigue, edema-related mobility limitations, recurrent infections due to hypoalbuminemia and immunosuppression, anxiety surrounding rapid functional decline, and psychosocial strain from diagnostic delays (median time to diagnosis is 6–12 months). Renal impairment correlates strongly with reduced physical functioning, depression prevalence (up to 40%), and diminished health-related quality of life scores on validated instruments like KDQOL-SF. Early recognition—through serum free light chain assay, 24-hour urine protein electrophoresis, and kidney biopsy with Congo red staining and mass spectrometry confirmation—is critical. Without treatment, median survival after renal involvement is <2 years; with modern risk-adapted therapy, 5-year survival exceeds 60%. However, persistent proteinuria and declining eGFR remain major drivers of long-term morbidity, dialysis dependence, and transplant eligibility challenges.

AL amyloidosis of the kidney is a systemic plasma cell dyscrasia characterized by the deposition of monoclonal immunoglobulin light chains (predominantly lambda) as insoluble, β-pleated sheet fibrils in renal tissue—particularly the glomeruli, interstitium, and vasculature. This leads to progressive proteinuria, nephrotic syndrome, declining glomerular filtration rate (GFR), and, if untreated, end-stage kidney disease (ESKD). Management requires a multidisciplinary approach coordinated by nephrology, hematology/oncology, cardiology, and pathology, with early diagnosis—confirmed via kidney biopsy with Congo red staining and mass spectrometry-based typing—being critical to prognosis.

Conservative treatment forms the essential supportive backbone of care. Strict blood pressure control (<130/80 mmHg) using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) is first-line to reduce intraglomerular pressure and attenuate proteinuria; however, these agents must be titrated cautiously in patients with reduced renal perfusion or hyperkalemia. Sodium restriction (<2 g/day) and fluid management are vital to mitigate edema and prevent volume overload, especially in those with concomitant cardiac amyloidosis. Diuretic therapy—typically loop diuretics (e.g., furosemide or torsemide), often combined with thiazide-like agents (e.g., metolazone) for synergistic effect—is employed judiciously to avoid prerenal azotemia. Nutritional support includes moderate protein intake (0.8–1.0 g/kg/day) to balance nitrogen requirements without exacerbating proteinuria or uremic toxicity; excessive protein restriction is discouraged due to risks of malnutrition and sarcopenia. Lipid-lowering therapy (e.g., high-intensity statins) addresses dyslipidemia common in nephrotic syndrome, while prophylactic anticoagulation may be considered in patients with serum albumin <2.5 g/dL and additional thrombotic risk factors, given the hypercoagulable state associated with AL amyloidosis.

Pharmacologic therapy targets the underlying clonal plasma cell disorder to halt production of pathogenic light chains. First-line regimens include bortezomib-based combinations: CyBorD (cyclophosphamide, bortezomib, dexamethasone) remains the most widely validated induction regimen, achieving hematologic response in ~70% of patients and renal response in ~40–50% at 6 months. Daratumumab—anti-CD38 monoclonal antibody—has revolutionized treatment; Dara-CyBorD demonstrates superior depth and speed of response, with ≥VGPR (very good partial response) rates exceeding 85% and significantly improved renal response kinetics. For transplant-ineligible patients or those with high-risk cytogenetics, daratumumab monotherapy or daratumumab–lenalidomide–dexamethasone (DRd) offer effective alternatives. Autologous stem cell transplantation (ASCT) remains an option for select patients aged <65 years with adequate cardiac function (NT-proBNP <3,300 ng/L, troponin T <0.06 ng/mL, no significant low-voltage QRS on ECG), achieving durable hematologic remission in >60% but carries substantial peri-transplant mortality risk (~5–10%) in amyloid cohorts. Novel agents under investigation include venetoclax (for t(11;14)-positive cases), bispecific antibodies, and anti-fibril monoclonal antibodies (e.g., NI006), though none are yet standard-of-care.

Surgical intervention has a highly limited role. Kidney transplantation is not contraindicated per se but is reserved exclusively for patients achieving sustained, deep hematologic response (≥CR for ≥6 months) with stable organ function and no evidence of active systemic amyloid deposition. Graft survival is comparable to non-amyloid recipients when stringent selection criteria are applied; however, recurrence—though rare (<5% at 5 years)—can occur if minimal residual disease persists. Combined heart-kidney transplantation is exceptionally rare and only considered in highly selected patients with isolated cardiac and renal involvement and complete hematologic remission. Surgical debulking or amyloid-directed procedures have no established efficacy and are not performed.

Treatment advantages in China reflect rapid integration of global standards with unique infrastructural and pharmacoeconomic strengths. Major academic centers—including Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—offer comprehensive amyloidosis programs with on-site mass spectrometry for definitive amyloid typing, rapid-turnaround bone marrow and fat pad biopsies, and multidisciplinary tumor boards. Daratumumab and bortezomib are now included in China’s National Reimbursement Drug List (NRDL), substantially reducing out-of-pocket costs. Domestic biosimilars (e.g., bortezomib biosimilars approved by NMPA) further improve accessibility. Moreover, China’s centralized electronic health records and national amyloidosis registry facilitate longitudinal outcome tracking and real-world evidence generation. Clinical trial participation is robust, with Chinese sites enrolling heavily in global phase III studies (e.g., ANDROMEDA, APOLLO-B), accelerating access to novel therapies. Importantly, traditional Chinese medicine (TCM) adjuncts—such as Huangqi (Astragalus membranaceus) formulations—are sometimes integrated under nephrologist supervision for symptom palliation (e.g., fatigue, edema), though rigorous evidence for disease-modifying effects remains lacking and TCM use must never delay or replace evidence-based anti-plasma cell therapy.

Recovery and long-term follow-up require structured, lifelong monitoring. Patients should undergo hematologic assessment (serum free light chain assay, immunofixation, bone marrow biopsy if indicated) every 3 months for the first year, then quarterly for two years, and biannually thereafter if stable. Renal monitoring includes 24-hour urine protein, serum creatinine/eGFR, and albumin every 1–3 months initially. Echocardiography and NT-proBNP are mandatory for cardiac surveillance, even in asymptomatic patients. Vaccination against pneumococcus, influenza, and SARS-CoV-2 is strongly recommended due to inherent immune dysfunction and treatment-related immunosuppression. Psychosocial support—including counseling and patient advocacy groups (e.g., China Amyloidosis Alliance)—is integral, given the chronic, unpredictable course and high symptom burden. Patients must be counseled to avoid NSAIDs (risk of acute kidney injury), herbal nephrotoxins (e.g., aristolochic acid-containing herbs), and unregulated supplements. Finally, pregnancy is strongly discouraged during active disease or within 12 months of completing cytotoxic therapy due to teratogenic risk and hemodynamic stress on compromised kidneys and heart.